- Home
- NBIX vs EXEL Comparison
NBIX vs EXEL Comparison
Compare NBIX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | EXEL |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.1B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NBIX | EXEL |
|---|---|---|
| Price | $137.43 | $42.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $176.24 | $46.05 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.44 | ★ 53.55 |
| EPS | ★ 4.19 | 2.38 |
| Revenue | ★ $2,682,700,000.00 | $2,288,218,000.00 |
| Revenue This Year | $23.55 | $9.65 |
| Revenue Next Year | $19.18 | $12.03 |
| P/E Ratio | $32.13 | ★ $17.95 |
| Revenue Growth | ★ 19.61 | 9.93 |
| 52 Week Low | $84.23 | $32.30 |
| 52 Week High | $160.18 | $49.62 |
Technical Indicators
Market Signals| Indicator | NBIX | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 40.36 |
| Support Level | $132.75 | $43.00 |
| Resistance Level | $138.74 | $45.37 |
| Average True Range (ATR) | 3.36 | 1.48 |
| MACD | 0.55 | -0.32 |
| Stochastic Oscillator | 86.35 | 4.13 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.